Literature DB >> 31897761

Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.

Masashi Hashimoto1, Yasuhiro Shirakawa2, Naoaki Maeda1, Shunsuke Tanabe1, Kazuhiro Noma1, Kazufumi Sakurama3, Kuniaki Katsui4, Masahiko Nishizaki1, Toshiyoshi Fujiwara1.   

Abstract

BACKGROUND: Locally advanced esophageal cancer (EC) invading surrounding organs (T4b) is difficult to treat. In general, definitive chemoradiotherapy (d-CRT) has been chosen as treatment for such cases. However, the outcome has not been good. Recently, the effectiveness of d-CRT with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) has been reported. Furthermore, surgery after d-CRT has a better prognosis than d-CRT alone in some reports, although it has a high risk of surgical complications. This study investigated the effectiveness and safety of induction DCF-RT.
METHODS: The subjects were EC patients who underwent induction DCF-RT in Okayama University Hospital between January 2011 and December 2017. Their background characteristics, treatment details, histopathological factors, adverse events during CRT, postoperative complications, and overall survival (OS) were assessed.
RESULTS: A total of 16 cases were performed induction DCF-RT. In 10 cases, death occurred, with 9 cancer-related deaths, and 1 death due to other disease. For all cases, OS was 37.5% at 3 years. 12 cases underwent esophagectomy after DCF-RT. Their OS was 50% at 3 years. 13 patients (81.3%) had Grade 3 febrile neutropenia. In 7 cases (62.5%), fasting for the treatment of diarrhea was needed. Three patients (25%) developed anastomotic leakage. Some recurrent laryngeal nerve paralysis was observed in 6 cases (50%).
CONCLUSION: Although the rates of adverse events and surgical complications were slightly higher than in past reports, they were acceptable. It is useful to perform induction DCF-RT for T4b EC.

Entities:  

Keywords:  Chemoradiotherapy; DCF-RT; Esophageal cancer; Neoadjuvant chemoradiotherapy; T4b

Mesh:

Substances:

Year:  2020        PMID: 31897761     DOI: 10.1007/s10388-019-00709-5

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


  16 in total

1.  Indications and operative techniques for combined aortoesophageal resection.

Authors:  Y Ichiyoshi; H Kawahara; S Taga; I Yoshino; T Ohsaki; H Kohno; K Yasumoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-07

2.  Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Authors:  Yuri Jeong; Jong Hoon Kim; Sung-Bae Kim; Dok Hyun Yoon; Seung Il Park; Yong Hee Kim; Hyeong Ryul Kim; Hwoon Yong Jung; Gin Hyug Lee; Jin-Sook Ryu
Journal:  J Surg Oncol       Date:  2013-12-02       Impact factor: 3.454

3.  Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer.

Authors:  Manabu Emi; Jun Hihara; Yoichi Hamai; Yoshiro Aoki; Morihito Okada; Masahiro Kenjo; Yuji Murakami
Journal:  Cancer Chemother Pharmacol       Date:  2012-03-02       Impact factor: 3.333

4.  Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).

Authors:  Katsuhiko Higuchi; Shouko Komori; Satoshi Tanabe; Chikatoshi Katada; Mizutomo Azuma; Hiromichi Ishiyama; Tohru Sasaki; Kenji Ishido; Natsuya Katada; Kazushige Hayakawa; Wasaburo Koizumi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-24       Impact factor: 7.038

5.  Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).

Authors:  Kenichi Nakamura; Ken Kato; Hiroyasu Igaki; Yoshinori Ito; Junki Mizusawa; Nobutoshi Ando; Harushi Udagawa; Yasuhiro Tsubosa; Hiroyuki Daiko; Shuichi Hironaka; Haruhiko Fukuda; Yuko Kitagawa
Journal:  Jpn J Clin Oncol       Date:  2013-04-26       Impact factor: 3.019

Review 6.  Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery.

Authors:  Tomoki Makino; Yuichiro Doki
Journal:  Ann Thorac Cardiovasc Surg       Date:  2011       Impact factor: 1.520

7.  Residual carcinoma cells after chemoradiotherapy for esophageal squamous cell carcinoma patients: striving toward appropriate judgment of biopsy.

Authors:  F Fujishima; Y Taniyama; Y Nakamura; H Okamoto; Y Ozawa; K Ito; H Ishida; T Konno-Kumagai; A Kasajima; S Taniuchi; M Watanabe; T Kamei; H Sasano
Journal:  Dis Esophagus       Date:  2018-07-01       Impact factor: 3.429

8.  Impact of Preoperative Neutrophil to Lymphocyte Ratio and Postoperative Infectious Complications on Survival After Curative Gastrectomy for Gastric Cancer: A Single Institutional Cohort Study.

Authors:  Yasuhiko Mohri; Koji Tanaka; Yuji Toiyama; Masaki Ohi; Hiromi Yasuda; Yasuhiro Inoue; Masato Kusunoki
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 9.  Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation.

Authors:  K Kono; K Mimura; R Kiessling
Journal:  Cell Death Dis       Date:  2013-06-20       Impact factor: 8.469

10.  A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.

Authors:  Hironaga Satake; Makoto Tahara; Satoshi Mochizuki; Ken Kato; Hiroki Hara; Tomoya Yokota; Naomi Kiyota; Takayuki Kii; Keisho Chin; Sadamoto Zenda; Takashi Kojima; Hideaki Bando; Tomoko Yamazaki; Satoru Iwasa; Yoshitaka Honma; Satoru Hamauchi; Takahiro Tsushima; Atsushi Ohtsu
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

View more
  6 in total

Review 1.  Surgical strategies for treatment of clinical T4 esophageal cancer in Japan.

Authors:  Kazuhiko Yamada; Kyoko Nohara; Naoki Enomoto; Hitomi Wake; Syusuke Yagi; Masayoshi Terayama; Daiki Kato; Chizu Yokoi; Yasushi Kojima; Hidetsugu Nakayama; Norihiro Kokudo
Journal:  Glob Health Med       Date:  2021-12-31

2.  Prognosis of patients with esophageal squamous cell carcinoma undergoing surgery versus no surgery after neoadjuvant chemoradiotherapy: a retrospective cohort study.

Authors:  Jiawei Li; Baofu Chen; Xia Wang; Congcong Xu; Dong Chen; Kanghao Zhu; Zixian Jin; Hongbin Qiu; Jianfei Shen; Minhua Ye
Journal:  J Gastrointest Oncol       Date:  2022-06

3.  Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.

Authors:  Noriyuki Nishiwaki; Kazuhiro Noma; Tomoyoshi Kunitomo; Masashi Hashimoto; Naoaki Maeda; Shunsuke Tanabe; Kazufumi Sakurama; Yasuhiro Shirakawa; Toshiyoshi Fujiwara
Journal:  Esophagus       Date:  2022-07-06       Impact factor: 3.671

4.  The efficacy of cisplatin and low-temperature plasma radiofrequency ablation in advanced laryngeal cancer patients and on the serum survivin levels.

Authors:  Biao Xing; Baoqiang Dai; Qiang Wang; Guoli Li; Jinhua Ma
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 5.  Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Mahshad Kalantari; Reza Mohammadinejad; Tahereh Javaheri; Gautam Sethi
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

6.  A retrospective study comparing definitive chemoradiotherapy vs. chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy.

Authors:  Tian Zhang; Zhoubo Guo; Xi Chen; Jie Dong; Hongjing Jiang; Peng Tang; Ping Wang; Dong Qian; Wencheng Zhang; Qingsong Pang
Journal:  Radiat Oncol       Date:  2022-08-23       Impact factor: 4.309

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.